BioNTech (NASDAQ:BNTX) Research Coverage Started at Argus

Posted by Brian Himes on Oct 11th, 2026

Argus started coverage on shares of BioNTech (NASDAQ:BNTX – Free Report) in a report published on Thursday, MarketBeat Ratings reports. The firm issued a hold rating on the stock.

Several other research analysts also recently weighed in on the company. Wall Street Zen downgraded BioNTech from a “hold” rating to a “sell” rating in a research note on Saturday, August 8th. Morgan Stanley lowered their price objective on BioNTech from $115.00 to $114.00 and set an “overweight” rating on the stock in a research note on Wednesday. Citigroup dropped their price objective on shares of BioNTech from $130.00 to $125.00 and set a “buy” rating on the stock in a report on Wednesday, August 5th. UBS Group reiterated a “buy” rating on shares of BioNTech in a research report on Wednesday, September 16th. Finally, BMO Capital Markets downgraded shares of BioNTech from an “outperform” rating to a “market perform” rating and reduced their target price for the stock from $128.00 to $105.00 in a research note on Tuesday, September 8th. One research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, BioNTech currently has a consensus rating of “Moderate Buy” and an average price target of $125.69.

Check Out Our Latest Stock Analysis on BNTX

BioNTech Trading Up 5.3%

NASDAQ:BNTX opened at $96.96 on Thursday. BioNTech has a 12 month low of $79.52 and a 12 month high of $124.00. The company has a current ratio of 7.85, a quick ratio of 7.80 and a debt-to-equity ratio of 0.01. The firm’s 50 day moving average is $99.17 and its 200 day moving average is $95.17. The stock has a market capitalization of $24.52 billion, a PE ratio of -12.38 and a beta of 1.25.

BioNTech (NASDAQ:BNTX – Get Free Report) last announced its quarterly earnings data on Tuesday, August 4th. The company reported ($2.53) earnings per share for the quarter, missing the consensus estimate of ($2.40) by ($0.13). The firm had revenue of $122.31 million for the quarter, compared to the consensus estimate of $180.18 million. BioNTech had a negative net margin of 63.54% and a negative return on equity of 6.86%. BioNTech’s revenue for the quarter was down 59.5% on a year-over-year basis. During the same period last year, the company posted ($1.60) earnings per share. Sell-side analysts expect that BioNTech will post -6.33 earnings per share for the current year.

Insider Activity

In related news, CEO Ugur Sahin sold 36,209 shares of the stock in a transaction dated Friday, October 9th. The stock was sold at an average price of $95.37, for a total transaction of $3,453,252.33. Following the sale, the chief executive officer owned 36,209 shares of the company’s stock, valued at approximately $3,453,252.33. This represents a 50.00% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 807,209 shares of company stock worth $79,246,837. Insiders own 19.20% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. Farther Finance Advisors LLC increased its position in shares of BioNTech by 31.5% during the third quarter. Farther Finance Advisors LLC now owns 493 shares of the company’s stock valued at $48,000 after buying an additional 118 shares during the period. Quintet Private Bank Europe S.A. lifted its holdings in shares of BioNTech by 232.8% in the third quarter. Quintet Private Bank Europe S.A. now owns 1,917 shares of the company’s stock worth $188,000 after buying an additional 1,341 shares in the last quarter. Engineers Gate Manager LP boosted its position in shares of BioNTech by 17.3% in the second quarter. Engineers Gate Manager LP now owns 12,433 shares of the company’s stock valued at $1,157,000 after acquiring an additional 1,833 shares during the period. Integrated Wealth Concepts LLC bought a new position in shares of BioNTech in the second quarter valued at approximately $39,000. Finally, Nykredit A S purchased a new position in BioNTech during the second quarter valued at approximately $293,000. Hedge funds and other institutional investors own 15.52% of the company’s stock.

Trending Headlines about BioNTech

Here are the key news stories impacting BioNTech this week:

Positive Sentiment: Biotech-sector momentum offered a modest tailwind after Moderna’s inclusion in the Nasdaq-100 triggered a sharp move in its shares, while BioNTech also traded higher alongside other major vaccine companies. Moderna Climbs 5% on NASDAQ 100 Entry; Pfizer Inches Higher, BioNTech Ticks Up
Neutral Sentiment: Argus initiated coverage with a Hold rating, adding a cautious view but no immediate change to the company’s fundamentals. Argus coverage reference
Neutral Sentiment: A report stating that short interest totaled zero shares implies no measurable short-squeeze pressure. The figure may reflect a reporting or data issue and should be interpreted cautiously.
Negative Sentiment: CEO Ugur Sahin sold 36,209 shares for approximately $3.45 million on October 9 and another 27,000 shares for about $2.49 million on October 8. The transactions were executed under a pre-arranged Rule 10b5-1 plan, which reduces their significance as discretionary signals, but the sales substantially reduced his direct ownership. BioNTech CEO SEC filing
Negative Sentiment: The latest quarterly results showed continuing commercial pressure: revenue fell 59.5% year over year to $122.31 million, below the $180.18 million consensus estimate, while the company reported a loss of $2.53 per share. Analysts expect a full-year loss, underscoring the need for BioNTech’s pipeline to offset declining COVID-19 vaccine revenue.

BioNTech Company Profile

(Get Free Report)

BioNTech SE is a biotechnology company headquartered in Mainz, Germany, focused on developing therapies and vaccines for cancer and other serious diseases. The company’s research platform includes messenger RNA (mRNA), individualized cancer vaccines, immune-modulating therapies, cell therapies, and protein-based therapeutics.

BioNTech is best known for developing the Comirnaty COVID-19 vaccine in collaboration with Pfizer. Comirnaty uses mRNA technology to help stimulate an immune response against COVID-19 and has been distributed in markets around the world.